Carbone A, Gloghini A, Volpe R
Division of Pathology, Instituto Nazionale di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.
Virchows Arch A Pathol Anat Histopathol. 1992;420(6):527-32. doi: 10.1007/BF01600258.
Morphological and immunohistological studies were carried out on a series of 137 lymphomas including CD30+ anaplastic large cell (ALC) lymphomas (48 cases) and non-lymphocyte predominant Hodgkin's disease (HD) (89 cases), with the aim of assessing in situ expression of a combination of antibodies including anti-CD30/BerH2, epithelial membrane antigen (EMA), CD15 and CD45, in addition to other monoclonal antibodies suitable for paraffin tissues. A greater proportion of cases of ALC lymphomas than of HD exhibited positivity for CD45 (91.7% vs 17.6%), EMA (56.2% vs 4.5%), CD43 (53.6% vs 13.1%) and CD45RO (39.5% vs 3.5%), whereas Reed-Sternberg (RS) cells in HD most frequently expressed CD15 (93.2% vs 20.8%) antigen. Moreover, in 35 of 48 (72.9%) ALC lymphomas tumour cells expressed the CD30+, CD45+, CD15-, EMA- or + phenotypic profile, while in the same percentage (62/85) of HD cases RS cells were found to express the CD30+, CD45-, CD15+, EMA- profile. This study suggests that the differential expression of CD45, EMA, and CD15 may be used in the separation of ALC lymphomas and HD. However, co-expression of CD30, CD45 and CD15 antigens by RS cells in HD (14/85 cases, 16.5% in this series) and by tumour cells in ALC lymphomas (9/48 cases, 18.7% in this series) may be encountered in a non-negligible fraction of cases.
对137例淋巴瘤进行了形态学和免疫组织学研究,其中包括CD30 +间变性大细胞(ALC)淋巴瘤(48例)和非淋巴细胞为主型霍奇金病(HD)(89例),目的是评估包括抗CD30 / BerH2、上皮膜抗原(EMA)、CD15和CD45在内的一组抗体的原位表达,以及其他适用于石蜡组织的单克隆抗体。与HD相比,ALC淋巴瘤病例中CD45(91.7%对17.6%)、EMA(56.2%对4.5%)、CD43(53.6%对13.1%)和CD45RO(39.5%对3.5%)呈阳性的比例更高,而HD中的里德 - 斯腾伯格(RS)细胞最常表达CD15抗原(93.2%对20.8%)。此外,在48例ALC淋巴瘤中的35例(72.9%)中,肿瘤细胞表达CD30 +、CD45 +、CD15 -、EMA - 或 + 的表型特征,而在相同比例(62/85)的HD病例中,发现RS细胞表达CD30 +、CD45 -、CD15 +、EMA - 的特征。这项研究表明,CD45、EMA和CD15的差异表达可用于区分ALC淋巴瘤和HD。然而,在不可忽略的一部分病例中,可能会遇到HD中的RS细胞(本系列中14/85例,16.5%)和ALC淋巴瘤中的肿瘤细胞(本系列中9/48例,18.7%)共表达CD30、CD45和CD15抗原的情况。